c-Myc Regulates Transcriptional Pause Release

The Myc family of transcription factors are well-known oncoproteins, and the c-Myc oncogene is expressed in both embryonic stem cells and cancer cells. It is also a key regulator of cellular proliferation. A new study published in...Read More

Celgene to Acquire Abraxis BioScience
Celgene and Abraxis BioScience jointly announced the signing of a definitive merger agreement, under which Celgene has agreed to...

Infinity and Intellikine to Develop Therapies Targeting PI3K Isoforms
Infinity Pharmaceuticals and Intellikine announced an agreement, under which Infinity obtained ...

Sanofi-aventis to Acquire TargeGen
TargeGen has agreed to be acquired by Sanofi-aventis. Formed in 2001, TargeGen’s most advanced drug candidate is...

MorphoSys and Xencor Collaborate for Clinical Antibody Program
MorphoSys and Xencor announced the signing of a worldwide exclusive license...

Read More

Insulin Receptor Conveys Intrinsic Resistance to IGF-1R Targeted Therapy Increased signaling through the insulin-like growth factor (IGF) pathway has been...

Regression of CRPC by a Small-molecule Inhibitor of Androgen Receptor
Androgen ablation therapy causes a temporary reduction in prostate cancer tumor burden. Unfortunately...

Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-deficient Metastatic Lung Tumors
Genetic analyses and gene expression profiling of primary human lung tumors have identified several aberrant signaling...

Read More

Avastin Meets Primary Endpoint in a Second Phase III Study in Ovarian Cancer
Genentech announced that a second large, Phase III, international study showed...

Afinitor More than Doubles PFS in Advanced Pancreatic NET

Novartis announced the results of a Phase III study, which showed that Afinitor...

Eisai Announces Results of Phase III Study of Dacogen in AML
Eisai announced preliminary results from a randomized Phase III clinical trial of...

GDC-0449 does not Meet Primary Endpoint in 1^st Line mCRC
Curis announced top line results from a Phase II clinical trial conducted by Roche and Genentech of ...

Read More

At SMARTANALYST, we support the decision-making process for licensing, business development, new product planning, and R&D groups within pharmaceutical and bio tech companies. We currently work with leading pharmaceutical and biotech firms globally.

CLICK HERE to visit SMARTANALYST

pAkt at Ser473 Predicts Benefit of Paclitaxel Therapy in Breast Cancer
Akt is a serine/threonine protein kinase that has been implicated in the pathogenesis...

A MicroRNA Targeting Dicer for Metastasis Control
Although specific microRNAs (miRNAs) can be upregulated in cancer, global miRNA downregulation is...

RT and Endpoint PCR Assays for Detecting Mutations in PI3K Oncogene
The PI3K pathway is mutated in more cancer patients than any other, playing a significant role in...

Monitoring Cancer Therapy Using RECAF Blood Test
BioCurex announced its first set of results supporting the use of RECAF blood test to...

Read More

FDA Rejects Roche's Avastin for Breast Cancer
A FDA panel dealt a blow to Roche's multibillion-dollar cancer drug Avastin on...

FDA Approves Tasigna for Newly Diagnosed CML Patients
Following a priority review, the FDA has approved Tasigna (nilotinib) for the treatment of adult patients with...

Cabazitaxel Injection Approved by FDA after Priority Review
Sanofi-aventis announced that the FDA has granted marketing authorization for Jevtana (cabazitaxel) injection...

Pfizer Announces Voluntary Withdrawal of Mylotarg for AML from US Market
Pfizer will discontinue the commercial availability of Mylotarg (gemtuzumab ozogamicin for injection...

Read More